What Indian Pharma Is Really Buying
Sun Pharma's roughly $11.75 billion all cash deal for Organon is one of the largest overseas acquisitions by an Indian drugmaker. It has also started a wider conversation about where the industry is heading.
A Wider Conversation About Pharma M&A
BioSpectrum's feature brings together voices from OPPI, ICRA, Grant Thornton Bharat, Frost & Sullivan and leading law firms on why big M&A is picking up, what makes integration so hard, and whether more billion dollar deals are on the way.
From Manufacturing to Global Market Ownership
The common thread is a move away from manufacturing for the world towards owning more of the global value chain, through specialty portfolios, biosimilars and direct access to regulated markets.
HRV Pharma's Perspective
Sharing his view, HRV Pharma's Hari Kiran Chereddi points out that a deal like this isn't about buying manufacturing capability. It is about brand value, relationships with doctors, regulatory standing across markets and pricing power, a shift he reads as a sign the industry has matured.
Read the full feature on BioSpectrum.
